Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) FCF Margin (2016 - 2025)

Historic FCF Margin for Gyre Therapeutics (GYRE) over the last 16 years, with Q3 2025 value amounting to 12.98%.

  • Gyre Therapeutics' FCF Margin rose 89300.0% to 12.98% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.7%, marking a year-over-year increase of 48200.0%. This contributed to the annual value of 5.63% for FY2024, which is 209500.0% down from last year.
  • As of Q3 2025, Gyre Therapeutics' FCF Margin stood at 12.98%, which was up 89300.0% from 7.0% recorded in Q2 2025.
  • Gyre Therapeutics' 5-year FCF Margin high stood at 41.67% for Q4 2022, and its period low was 1777.65% during Q2 2021.
  • For the 5-year period, Gyre Therapeutics' FCF Margin averaged around 384.74%, with its median value being 3.82% (2023).
  • As far as peak fluctuations go, Gyre Therapeutics' FCF Margin plummeted by -16308900bps in 2021, and later skyrocketed by 15524300bps in 2023.
  • Gyre Therapeutics' FCF Margin (Quarter) stood at 724.43% in 2021, then soared by 106bps to 41.67% in 2022, then plummeted by -91bps to 3.82% in 2023, then tumbled by -353bps to 9.66% in 2024, then soared by 234bps to 12.98% in 2025.
  • Its last three reported values are 12.98% in Q3 2025, 7.0% for Q2 2025, and 1.14% during Q1 2025.